一个患有myxedema危机的患者的急性帕金森症:一个病例报告
Rajat Gupta1, Shakun Chaudhary2, Vivek Sood1
1Department of Medicine, Dr Rajendra Prasad Government Medical College Kangra at Tanda, Kangra, Himachal Pradesh 176001, India.
Medicine international
|July 15, 2024
概括
这项案例研究突出了希汉综合征的罕见表现,即混合危机. 早期诊断和治疗myxedema危机,以及识别二次帕金森症,导致成功的患者恢复.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 案例报告 案例报告
背景情况:
- 希恩综合征是一种罕见的疾病,会导致下垂体病,往往会以潜伏的方式出现.
- 甲状腺功能低下症的严重表现 - - 甲状腺瘤危机 (myxedema crisis) 可能是潜在的下垂体功能障碍的初始表现.
研究的目的:
- 描述一种独特的Sheehan综合症病例,最初呈现为混凝土危机.
- 强调在管理内分泌紧急情况后考虑持续的神经症状的次要原因的重要性.
主要方法:
- 一名31岁的女性呈现出改变的感官体,低温,低血压和心.
- 诊断工作包括甲状腺功能测试,垂体激素概况和神经成像 (MRI).
- 管理涉及治疗混合危机和随后的帕金森症.
主要成果:
- 该患者被诊断出患有二次性甲状腺功能低下症和泛甲状腺功能低下症,与希恩综合征一致.
- 尽管初步改善了myxedema危机治疗,但持续改变的传感器导致了急性帕金森症的诊断.
- 用莱沃西素,皮,后来使用莱沃多巴-卡比多巴的治疗导致了显著的临床改善.
结论:
- 希恩综合征可能不常见地表现为血危机.
- 持续的神经缺陷需要彻底调查共存的条件,如帕金森症.
- 对内分泌和神经方面的综合管理对于有利的结果至关重要.
相关概念视频
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
Myasthenia Gravis: Diagnostic Tests
753
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
753
Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
406
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
406
Depolarizing Blockers: Pharmocokinetics
317
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
317


